{"id":"04988","slug":"engineered-t-cells-that-target--04988","source":{"id":"04988","dataset":"techtransfer","title":"Engineered T Cells That Target a Recurrent ATM Mutation in Cancer Cells","description_":"<p>This technology is a human T cell engineered with a T cell receptor (TCR) that recognizes a mutated form of the DNA-repair protein ATM, presented on the HLA A*03:01 immune molecule. It offers a way to direct a patient’s own immune cells toward cancer cells that carry this mutation, while sparing cells with normal ATM.</p><p><h2>Description</h2>ATM is a protein that helps cells repair broken DNA. A subset of tumors carry a mutation at position 2695 of ATM, where the normal glycine is replaced by valine, alanine, cysteine or serine. Because this change exists only in tumor cells, a short fragment of the mutated protein displayed on the cell surface (by HLA A*03:01) can act as a tumor-specific marker for the immune system.\r<br>\r<br>The invention is a defined T cell receptor, made of an alpha chain and a beta chain with specified recognition regions, that binds this mutated fragment. T cells are modified to express the receptor, using nucleic acid delivered by a vector such as a viral vector. In T cells the natural TCR genes can be downregulated so the engineered receptor predominates. The resulting cells can be made from a patient’s own T cells and given back to the patient for cancer treatment.</p><p><h2>Applications</h2>- Autologous T cell therapy for cancers carrying ATM position 2695 mutations\r<br>- Personalized or genotype-guided oncology, pairing HLA and ATM mutation screening with treatment\r<br>- Companion diagnostic development to identify eligible patients\r<br>- Viral-vector or nucleic-acid delivery platforms for TCR-based therapeutics\r<br>- Combination regimens with other cancer immunotherapies</p><p><h2>Advantages</h2>- Targets a mutation-specific peptide, with reactivity to mutant ATM and none observed against wild-type ATM in vitro\r<br>- Recognizes several mutant forms at position 2695 (valine, alanine, cysteine, serine)\r<br>- Uses a defined receptor sequence that can be introduced by standard nucleic acid and vector approaches\r<br>- Supports use of the patient’s own cells (autologous)\r<br>- Allows downregulation of endogenous TCR chains, so the introduced receptor predominates</p><p><h2>Invention Readiness</h2>In vitro data</p><p><h2>IP Status</h2>US12,715,902</p><p></p>","tags":["Immuno-oncology"],"file_number":"04988","collections":[{"key":513,"name":"Cell & Gene Therapy"}],"meta_description":"Engineered T cells target a recurring ATM mutation (2695) via a defined TCR, enabling autologous, genotype-guided cancer immunotherapy.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":2.0,\"potential_impact\":3.0,\"readiness\":3.0,\"scalability\":2.0,\"timeliness\":1.0},\"weighted_score\":2.35,\"risks\":[\"Age of the technology (2019) reduces novelty and timeliness\",\"Readiness at TRL3 with in vitro data; no in vivo efficacy yet\",\"Scalability may be challenged by manufacturing autologous T cells and HLA restriction (A*03:01)\",\"Potential competition from newer TCR or CAR approaches; mutation-specific targeting may limit patient population\"],\"one_sentence_take\":\"Moderate novelty with targeted TCR approach; early proof with limited scalability and timeliness due to age and autologous platform constraints.\"}","lead_inventor_name":"Udai Kammula","lead_inventor_dept":"Med-Surgery","technology_type":"Therapeutic Modality","technology_subtype":"Cell Therapy - T Cell","therapeutic_areas":["Immunology","Oncology"],"therapeutic_indications":["Solid tumor"],"custom_tags":[],"all_tech_innovators":["Chetana Bhaskarla","Smriti Chaurasia","Udai Shankar Kammula","Ghanshyam Singh Yadav"],"date_submitted":"2019-05-10","technology_readiness_level":"3. Initial proof of concept, in-vivo"},"highlight":{},"matched_queries":null,"score":0.0}